Fischer Imaging plans to present a new version of its full-field digital mammography (FFDM) unit, SenoScan, at this year's RSNA show. SenoScan2 will continue to incorporate slot-scanning technology, cesium iodide CCD detectors, and 25-micron resolution, but will boast workflow improvements such as smart technique automatic response (STAR), wheelchair access, automatic paddle recognition, and an expanded family of soft-copy review workstations, SenoView and SenoView Plus.
SenoView and SenoView Plus are based on the integration of the SenoScan system and the recently FDA-cleared Cedara I-ReadMammo software for diagnosis and screening. The workstations are designed to help radiologists and technologists view current and prior film images, as well as images from multiple modalities, in a single format on a single workstation.
Additional workflow improvements Fischer will showcase include thumbnail logins for HIPAA compliance, integrated mammography reporting systems, and integrated CAD software that can be used not only for digital mammography, but also for ultrasound. These features will be available by the first quarter of 2005, according to the Denver-based company.
The company's MammoTest Select breast biopsy system will also get an upgrade, with new software (version 4.0) called Premium that will allow users with specific biopsy requirements to optimize and customize the procedure in printing, workflow, DICOM, and storage applications. Premium will also be available in the first quarter of 2005. Fischer will highlight the FDA's clearance of MammoTest for breast brachytherapy procedures.
For a glimpse of the future, Fischer will introduce its works-in-progress pipeline of products, based on the MammoTest and SenoScan platforms, that the company expects to launch in the next two to five years. These projects will include SenoScan Fused Imaging, which will integrate ultrasound, x-ray, tomosynthesis, and stereotactic imaging on upright units; using MammoTest with laser and gamma therapy applications; and performing integrated fused imaging ultrasound, as well as tomosynthesis 3D CT, on prone tables.
On the corporate relationship front, Fischer will be discussing the three-year agreement it inked with Philips Medical Systems of Andover, MA, for that vendor to sell SenoScan2 packaged with its own workstation, according to Fischer.
By Kate Madden Yee
AuntMinnie.com staff writer
November 10, 2004
Copyright © 2004 AuntMinnie.com
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
